Reported about 1 month ago
Septerna kicked off its market debut on Nasdaq with a remarkable 31% rise in shares, bringing its valuation to $970 million. The company's shares opened at $23.5, up from an IPO price of $18, following an upsized offering that raised $288 million. The biotech firm, backed by Goldman Sachs, focuses on developing therapies for G-protein-coupled receptors (GPCRs) and plans to advance its product research, particularly for hypoparathyroidism treatment.
Source: YAHOO